Jim Miller is president of PharmSource Information Services, Inc., and publisher of Bio/Pharmaceutical Outsourcing Report, tel. 703.383.4903, Twitter@JimPharmSource, email@example.com(, http://www.pharmsource.com/.
The trend of exits from the CMO industry looks to be gaining momentum.
As payers refuse to cover new drugs, CMOs take a hit.
The CMO industry's value proposition is limiting its market penetration.
Changes in company ownership shake up the CMO industry.
The R&D model is in transition and creating new demands on contract services providers.
Ongoing changes create new opportunities for CROs and CMOs.
Practicality of implementation should be a part of vision in the bio/pharmaceutical industry.
Are strategic partnerships in clinical research a model for CMC services?
Approvals of new drugs are on an upward swing, but only a few CMOs are benefiting.